Longitudinal Insights Into Childhood Onset Facioscapulohumeral Dystrophy
Author Information
Author(s): Jildou N. Dijkstra, MD, Helena T.M. Boon, MD, Anne Koekkoek, BSc, Rianne J.M. Goselink, MD, PhD, Maaike M. Pelsma, MSc, Nens Van Alfen, MD, PhD, Saskia L.S. Houwen-van Opstal, MD, PhD, Baziel G.M. Van Engelen, MD, PhD, Nicol C. Voermans, MD, PhD, Corrie E. Erasmus, MD, PhD
Primary Institution: Radboud University Medical Centre, Nijmegen, The Netherlands
Hypothesis
Understanding the natural history of childhood FSHD and identifying clinical and functional outcome measures are crucial for clinical care and future trials.
Conclusion
Despite disease progression, most children did not perceive worsening conditions, and quality of life improved over the study period.
Supporting Evidence
- Eighteen patients completed the 5-year follow-up, with a mean FSHD-CS increase of 1.6.
- 89% of participants did not perceive any change in their condition despite objective disease progression.
- Quality of life improved and fatigue levels decreased over the 5-year period.
Takeaway
This study followed kids with a muscle disease for five years to see how it affects them, and even though their condition got worse, they felt better overall.
Methodology
A prospective nationwide cohort study assessing 20 childhood-onset patients at baseline, 2 years, and 5 years using various clinical and functional tests.
Potential Biases
Potential bias due to the small sample size and the subjective nature of some assessments.
Limitations
The small cohort size and milder phenotype may limit generalizability, and the responsiveness of different outcome measures varies.
Participant Demographics
Eighteen patients aged 2–17 years at baseline, with a mean current age of 15.1 years.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website